Critical Supply Strategies for Biologic/Biosimilar Studies
As more approved biologics near patent expiration, the race to be first to market with a biosimilar alternative will intensify. Delays encountered during clinical studies can have a serious impact on competitive advantage, speed to market and the availability of lower-cost alternatives for patients.
Successfully maintaining product integrity and reliability of supply is a complex endeavor and one that is especially challenging for biologic and biosimilar studies.
Free on-demand webinar hosted by Catalent clinical logistics and supply chain experts Mark Woolf & John Samuels